阿拉丁(688179) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 542,303,196.29, an increase of 34.61% compared to the previous year[4] - Operating profit was RMB 130,448,878.49, reflecting a growth of 37.03% year-over-year[4] - Net profit attributable to shareholders was RMB 99,028,063.47, up 15.38% from the prior year[4] - Basic earnings per share decreased by 26.53% to RMB 0.36[4] - The weighted average return on equity was 9.42%, slightly up from 9.27% in the previous year[4] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 1,781,336,951.68, representing an 18.32% increase year-over-year[7] - Shareholders' equity attributable to the parent company was RMB 1,066,365,505.82, a growth of 2.89% compared to the previous year[7] Capital Changes - The company’s capital stock increased by 40.00% due to a rights issue executed during the reporting period[9] Revenue Contributions - The inclusion of Shanghai Yuan Ye Biotechnology Co., Ltd. in the consolidation scope from the second quarter contributed to revenue growth[7] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and unaudited, with the final figures to be confirmed in the annual report[10]